Hutchmed (#HCM) – agreements to divest joint venture interest for approx. $608m
- 2025-01-02 07:38:46
UK 15:34 Friday, 6 November 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2019 and thus far in 2020 (by net short position %, those in bold not on the list at the start of 2020) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...
From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2017 and thus far in 2018 (by net short position %) - and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...
The boy Moore and I do not want to seem like total spivs - we are long term investors. But....
Never tip Chinese stocks is a golden rule I broker a couple of months ago when tipping shares in Hutchison China MediTech (HCM) at an 870p offer on my Nifty Fifty website. All seemed to be plain sailing until…
Never buy Chinese stocks listed in London is a golden rule of mine. But I broke it last month tipping Hutchison China MediTech (HCM) at an 870p offer. They are now 960p bid after interims yesterday. So why break a golden rule and is there more to come for the shares?
Investment Case: Majority owned by Hutchison Whampoa, the Hong Kong-listed renowned multinational infrastructure, property, retail and telecommunications conglomerate including the likes of the ‘3’ mobile business, Hutchison China MediTech (HCM) is the holding company of a primarily China-based healthcare and drug development group. This includes growing businesses selling already established products and a drug research & development business which has developed strongly and looks to offer vast upside potential. This combination makes the shares a buy at an 870p offer price.
